Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Son Espases (19)

2024

  1. Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations

    Crohn's and Colitis 360, Vol. 6, Núm. 4

  2. Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus

    BMJ Open Gastroenterology, Vol. 11, Núm. 1

  3. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

2023

  1. Optimizing treatment of mild to moderate ulcerative colitis: CU-forum Delphi consensus

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 10, pp. 784-794

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  4. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  5. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  6. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2020

  1. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 2, pp. 97-105

2018

  1. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients

    Gastroenterologia y Hepatologia

2017

  1. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

2016

  1. Eficacia y efectividad de la terapia biológica en la Enfermedad Inflamatoria Intestinal. Estudio EFIFECT

    Gastroenterologia y Hepatologia, Vol. 39, Núm. 6, pp. 369-376

  2. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort

    Inflammatory Bowel Diseases, Vol. 22, Núm. 7, pp. 1662-1669

2013

  1. Does smoking influence Crohn's disease in the biologic era? the TABACROHN study

    Inflammatory Bowel Diseases, Vol. 19, Núm. 1, pp. 23-29

  2. High smoking cessation rate in Crohn's disease patients after physician advice - The TABACROHN Study

    Journal of Crohn's and Colitis, Vol. 7, Núm. 3, pp. 202-207

2010

  1. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: The RECLICU Study

    Journal of Crohn's and Colitis, Vol. 4, Núm. 6, pp. 629-636